Xilio TherapeuticsXLO
13F holders, Q4 2024 (December 31)At the end of Q4 2024, 35 institutions reported holding Xilio Therapeutics Inc. (XLO) in their 13F filings, up 2 from Q3 2024. 4 opened new positions and 5 sold out. The largest holders were Gilead Sciences, Inc. ($8.7M), Bain Capital Life Sciences Investors, LLC ($4.4M) and Rock Springs Capital Management LP ($2.9M). 2 famous investors held it, including Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio) and Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Xilio Therapeutics Inc.
- CUSIP
- 98422T100
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $128K |
| Exits | 5 | $101K |
All 13F filers, Q3 2024 → Q4 2024: 489,565 shares bought and 663,558 shares sold, net −173,993 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 35 holders
| Gilead Sciences, Inc. | 0.56% | — | 9,105,451 | $8.7M |
| Bain Capital Life Sciences Investors, LLC | 0.51% | No change | 4,566,817 | $4.4M |
| Rock Springs Capital Management LP | 0.11% | No change | 3,003,259 | $2.9M |
| Merck & Co., Inc. | 0.55% | — | 1,483,758 | $1.4M |
| Takeda Pharmaceutical Co. Ltd. | 5.33% | No change | 1,475,121 | $1.4M |
| FMR LLC | 0.00% | No change | 1,395,853 | $1.3M |
| Morgan Stanley | 0.00% | Reduce -34.2% | 1,001,359 | $956K |
| Vanguard Group Inc. | 0.00% | No change | 902,531 | $862K |
| AJU IB Investment Co., Ltd. | 0.62% | — | 667,742 | $638K |
| Geode Capital Management, LLC | 0.00% | Add +6.0% | 358,422 | $342K |
| Balyasny Asset Management L.P. | 0.00% | Add +26.0% | 343,230 | $328K |
| Renaissance Technologies | 0.00% | Add +11.4% | 296,617 | $283K |
| Trustees of Columbia University in the City of New York | 0.04% | — | 249,635 | $238K |
| UBS Group AG | 0.00% | Add +1485.2% | 249,401 | $238K |
| FIL Ltd | 0.00% | No change | 218,705 | $209K |
| BlackRock, Inc. | 0.00% | Add +0.6% | 76,086 | $73K |
| Bridgeway Capital Management, LLC | 0.00% | No change | 71,081 | $68K |
| Raymond James Financial Inc. | 0.00% | — | 50,086 | $48K |
| Susquehanna International Group, LLP | 0.00% | New | 49,093 | $47K |
| State Street Corp. | 0.00% | No change | 43,390 | $41K |
| Aptus Capital Advisors, LLC | 0.00% | New | 41,000 | $39K |
| Citadel Advisors | 0.00% | New | 40,316 | $39K |
| Northern Trust Corp. | 0.00% | No change | 39,208 | $37K |
| SevenBridge Financial Group, LLC | 0.01% | No change | 41,000 | $27K |
| Mariner, LLC | 0.00% | Reduce -1.3% | 25,000 | $24K |
| Steward Partners Investment Advisory, LLC | 0.00% | No change | 20,000 | $19K |
| XTX Topco Ltd | 0.00% | Reduce -46.1% | 12,870 | $12K |
| Two Sigma Investments, LP | 0.00% | Add +4.2% | 10,824 | $10K |
| Pinnacle Financial Group, LLC / IL | 0.00% | No change | 10,000 | $10K |
| Federation des caisses Desjardins du Quebec | 0.00% | New | 3,300 | $3K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -51.4% | 2,729 | $3K |
| Key Financial Inc | 0.00% | No change | 830 | $793 |
| Private Wealth Management Group, LLC | 0.00% | No change | 310 | $297 |
| Bank of America Corp. | 0.00% | Reduce -0.4% | 265 | $253 |
| JPMorgan Chase & Co. | 0.00% | Reduce -12.0% | 66 | $63 |
"% of holder's portfolio" is XLO's weight in each manager's 13F, not the share of Xilio Therapeutics Inc. the manager owns.